Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus
Fabien B Vincent, Laura Slavin, Alberta Y Hoi, Arthur Richard Kitching, Fabienne Mackay, James Harris, Rangi Kandane-Rathnayake, Eric F Morand
LUPUS SCIENCE & MEDICINE | BMJ PUBLISHING GROUP | Published : 2018
Objective: To characterise the clinical relevance of urinary macrophage migration inhibitory factor (uMIF) concentrations in patients with systemic lupus erythematosus (SLE). Methods: MIF, adjusted for urine creatinine, was quantified by ELISA in urine samples from 64 prospectively recruited patients with SLE. Serum MIF and urinary monocyte chemoattractant protein 1 (uMCP-1) were quantified by ELISA in a subset of patients (n = 39). Disease activity was assessed using the SLE Disease Activity Index-2000 (SLEDAI-2K) score. Results: uMIF was detectable in all patients with SLE. uMIF was positively correlated with overall SLEDAI-2K, was significantly higher in patients with SLE with high diseas..View full abstract
FM is recipient of fellowships from the NHMRC of Australia. EFM was supported by the Kim Jolly Lupus Research Trust, and the Monash lupus database has received support from Arthritis and Osteoporosis Victoria and unrestricted educational grants from Glaxosmithkline, UCB and Eli Lilly Australia.